未治疗卵巢癌中两种耐药机制的表达及其意义

为了解卵巢癌内在性的耐药机制，用免疫组织化学方法对３０例正常卵巢组织及术前未经治疗的７４例卵巢癌进行了Ｐ－糖蛋白（Ｐ－ｇｐ）与谷胱甘肽Ｓ－转移酶π（ＧＳＴ－π）的检测结果表明：正常卵巢组织中，Ｐ－ｇｐ与ＧＳＴ－π的阳性率分别为１８．９％及７４．３％，与对照组相比，均有显著性差异（Ｐ〈０．０５，Ｐ〈０．０１）。卵巢癌中，单独表达一种耐药标志的有３８例（５１．４％），同时表达两种耐药标志的有１４例（１

Expression of Two Resistance Mechanisms in Untreated Human Ovarian Carcinomas

To determine the intrinsic drug resistance mechanisms of ovarian carcinomas, thirty cases of normal ovary and 74 human epithelial ovarian carcinomas of pretherapeutic patients were analyzed for the presence of P-glycoprotein(P-gp) and glutathione S-transferase-π(GST-π) by means of immunohistochemistry. Results showed that P-gp and GST-π immunoreactivity were present in patient with ovarian caracinoma in 14(18.9%) and 55(74.3%)cases respectively, but showed negative reactions in normal ovary tissues. In the ovarian carcinomas investigated, single resistance marker was seen in 51.4% and two resistance markers in18.9% of the cases. The expression of P-gp and GST-π showed highly significant positive correlation (P＜0.01). The results suggested that there were resistance mechanisms caused by expression P-gp or/ and GST-π in untreated ovarian carcinomas.The expression of the two resistance markers might contribute to drug resistance in ovarian cancers.